Introduction
Multiple myeloma (MM) is characterized by the accumulation of clonal malignant plasma cells in the bone marrow (BM) and monoclonal protein in blood and/or urine. 1 Clinical features include increased risk for infection, pancytopenia, renal disease, hypercalcemia, and bone disease. Although conventional treatments achieve high response rates, disease relapse occurs as a result of acquired drug resistance. Novel agents including thalidomide, lenalidomide, and bortezomib can achieve responses in patients with relapsed and/or refractory MM, 2-5 but resistance develops to these agents. Thus, there is an urgent need for novel biologically-based treatment strategies in MM.
Accumulating evidence implicates RAS/MEK/ERK signaling pathway in pathogenesis of MM. First, specific mutations of N-RAS (Q61R) or RAF (V600E) resulting in highly-activated MEK/ERK pathway are associated with enhanced and selective sensitivity to MEK inhibition. 6 Second, MM cells in the BM microenvironment may also be more susceptible to ERK inhibition due to adhesioninduced ERK activation. ERK1/2 activation is induced in MM cells both by binding to bone marrow stromal cells (BMSCs) and associated cytokine secretion. 7, 8 Interleukin-6 (IL-6) and insulin growth factor-1 (IGF-1), two major growth, survival, and drug resistance factors for MM cells, stimulate cell proliferation and block apoptosis by activating this pathway. 1, [9] [10] [11] [12] [13] MEK and ERK activity is also induced by vascular endothelial growth factor (VEGF) and B-cell activating factor (BAFF) through autocrine and paracrine mechanisms; conversely, pharmacological only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From 5 inhibition of MEK/ERK signaling blocks MM cell proliferation and migration induced by these cytokines. 14, 15 Dexamethasone (Dex) is a major therapy for MM, and MEK inhibitors synergize with Dex. [16] [17] [18] 23, 24 This antiangiogenic effect of MEK/ERK pathway inhibition therefore represents additional potential mechanism of its anti-MM activity.
AZD6244, a novel oral and highly specific MEK1/2 inhibitor, 25, 26 induces sustained inhibition of ERK1/2 phosphorylation and tumor cell growth in human solid tumor xenograft models. It has now entered phase I clinical trials in patients with melanoma and non small cell lung cancer. 27, 28 In the present study, we investigated the impact of AZD6244 on MM cells and osteoclasts (OCs) within the BM microenvironment. Our in vitro and in vivo studies show that AZD6244 targets both MM cells and OCs in the BM milieu, and enhances cytotoxicity of both conventional and novel anti-MM agents. These preclinical in vitro and in vivo studies provide the framework for derived clinical trials to improve patient outcome in MM. 
Materials and Methods

Immunoblotting analysis
To determine whether AZD6244 inhibits baseline and cytokine-induced ERK phosphorylation, MM1S cells were starved and stimulated with indicated cytokines, in the presence or absence of the drug. Cell lysates were immunoblotted using specific Abs (Cell Signaling Technology, Beverly, MA). To determine whether AZD6244 altered expression of proteins involved in apoptosis, cell proliferation, survival, and cell cycle regulation, MM cells were incubated with drug for indicated time intervals, lysed, and subjected to immunoblotting, as in prior studies. 15 To measure AZD6244 induced caspase-dependent apoptosis in the BM milieu, MM1S cells were treated with or without AZD6244 for 24h, in the presence or absence of BMSCs; tumor cells (> 95% purity) were harvested, lysed, and immunoblotted using specific Abs, with anti-α-tubulin mAb as a loading control. 
Apoptosis assays
In vitro osteoclast (OC) culture
Peripheral blood mononuclear cells (PBMCs) were obtained from MM patients after informed consent. CD14+ OC precursor cells 31 were cultured for 7-14 days in ISCOV/10% FCS with receptor activator of NF-κB ligand (RANKL) (50 ng/mL; PeproTech, Rocky Hill, NJ), and macrophage-colony-stimulating factor (M-CSF; 25 ng/mL; Peprotech), in the presence or absence of AZD6244 (0-2 µM). Total RNA was prepared using the RNeasy kit (Qiagen) and subjected to RT-PCR using (25, or 50 mg/kg) or with the control vehicle alone. Tumor size was measured every day in 2D using a caliper; tumor volume was calculated using the formula: V= 0.5 X a X b 2 , where "a" and "b" are the long and short diameters of the tumor, respectively.
Animals were sacrificed when their tumors reached 2 cm 3 in diameter or when paralysis or major compromise in their quality of life occurred. At the time of the animals' death, tumors were excised. Survival was evaluated from the first day of treatment until death.
Statistical analysis
Statistical significance of differences observed in drug-treated compared with control cultures was determined using Student t test. The minimal level of significance was a p < 0.05. Regression analysis was used to calculate IC 50 of tested chemicals. The
Chou-Talalay method was used to assess synergistic or additive effects of combined therapies. 32 A combination index (CI) < 1.0 indicates synergism, and CI of 1.0 indicates additive activity. 8, 32 The tumor growth inhibition and survival of mice were determined using SigmaPlot analysis software (Systat Software, San Jose, CA).
Overall survival was measured using the Kaplan-Meier and log-rank method,
Results
AZD6244 specifically inhibits ERK activation and induces cytotoxicity in MM cells, regardless of sensitivity to conventional chemotherapy
only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From Baseline and cytokine-induced ERK phosphorylation was first examined in MM1S cells, which have been extensively studied to validate novel (bortezomib and lenalidomide) therapies in MM. MM1S cells were cultured with or without AZD6244 (10 nM), followed by IGF-1 (100 ng/ml) stimulation for indicated time intervals. Total cell lysates were prepared and subjected to immunoblotting using specific antibodies. AZD6244 completely blocked both constitutive and IGF-1-induced ERK phosphorylation (Fig. 1A) . In contrast, IGF-induced AKT phosphorylation was not inhibited. Similarly, pretreatment with AZD6244 completely blocked IL-6-or CD40L-induced ERK phosphorylation, without altering AKT activation. Thus AZD6244 at concentrations as low as 10 nM selectively inhibits constitutive and cytokine-induced ERK phosphorylation. We next examined the growth inhibitory effect of AZD6244 in a panel of MM lines sensitive or resistant to conventional therapies. MM lines were cultured for 2 days in the presence or absence of AZD6244, and DNA synthesis was then measured. AZD6244 significantly inhibited MM cell proliferation in a dosedependent fashion (Fig 1B) . Importantly, AZD6244 at concentrations as low as 20 nM inhibited growth of CD138-positive MM cells from 3 patients (Fig. 1C ).
Responses to AZD6244 and mutation status of RAS genes including NRAS and KRAS (codon 12 and 61) from patients with advanced disease were included in Fig.   1D . These results indicate that AZD6244 is also effective in advanced stages where MM cells are less dependent on factors produced by the microenvironment.
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AZD6244 induces MM cell cytotoxicity in the presence of IL-6 and BMSCs
Since IL-6 is a MM growth, survival, and drug resistance factor, 1 to BMSCs augments IL-6 secretion from BMSCs, which is also blocked by AZD6244 (Fig. 2D) . Finally, AZD6244 has minimal cytotoxic effects on BMSCs derived from MM patients, since it does not inhibit their growth and viability at concentrations (50 µM) which are cytotoxic against MM cells (Fig. 2E) . These results indicate that neither IL-6 nor BMSCs protect against AZD6244-triggered cytotoxicity in MM cell lines and patient MM cells.
AZD6244 induces caspase 3-dependent apoptosis in MM cells adherent to BMSCs
To further confirm whether AZD6244 triggers apoptotic signaling in MM cells adherent to BMSCs, we next measured caspase 3 activity in drug-treated Dexonly.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From resistant MM1R cells, cultured with or without BMSCs. Caspase 3 activity was triggered by AZD6244 in these MM cells in a dose-dependent fashion, even in the presence of BMSCs, whereas caspase 3 activation was not induced in BMSCs (Fig.   3A) . AZD6244 similarly induced caspase 3 activity in Dex-sensitive MM1S cells adherent to BMSCs (data not shown). Importantly, AZD6244 (200 nM) also inhibits growth of patient MM cells adherent to BMSCs, associated with increased caspase 3 activity (Fig. 3B) . To confirm targeting of ERK1/2, we performed immunoblotting of lysates from MM1S cells cultured alone or with BMSCs, in the presence or absence of AZD6244. As in our previous studies 7, 8 , adhesion of MM1S cells to BMSCs significantly induced phosphorylation of ERK1/2 (Fig. 3C) . Importantly, AZD6244 inhibits constitutive and adhesion-induced ERK1/2 activation in MM1S cells. Drug (2 µM) also significantly induces cleavage of PARP and caspase 3 in MM1S cells cultured with BMSCs (Fig. 3C) . These results strongly suggest that ERK inhibition by AZD6244 targets MM cells in the BM microenvironment.
Functional sequelae of ERK inhibition by AZD6244 in MM cells
To delineate the mechanism whereby AZD6244 mediates MM cell growth inhibition, we next examined the cell cycle profile of INA-6 cells cultured with control media or AZD6244 (2 µM). As shown in Fig. 4A, AZD6244 , in a time-dependent manner, induces a progressive increase in sub-G 0 /G 1 phase cells. A dose-dependent increment in apoptotic fraction induced by AZD6244 (0.1-10 µM) is further evidenced by increased PI+/annexin V+ INA-6 cells (Fig. 4B) . Treatment of patient MM cells with AZD6244 (0.2 µM) for 2 days similarly increases PI+/annexin V+ apoptotic cells, confirming that AZD6244 significantly induces cytotoxicity and apoptosis (Fig. 4C) .
We next examined the molecular sequelae triggered by AZD6244 using immunoblotting (Fig. 4D) . For
resistance is acquired to these two novel agents. We therefore next examined whether AZD6244 enhances cytotoxicity of these novel agents against MM1S cells.
AZD6244 increases bortezomib-induced (Fig. 5B , CI = 1.0; p < 0.04; n = 3) and lenalidomide-induced (Fig. 5C , CI = 1.0; p < 0.05; n=3) cytotoxicity.
Most recently, we have shown that AKT inhibition by perifosine is associated with significant anti-MM activity in vitro and in vivo 8 , providing the preclinical rationale for a phase I clinical trial in MM. Using a pharmacological ERK inhibitor U0126, we also recently showed that ERK inhibition synergistically augments perifosine-induced cytotoxicity in MM1S and MM1R MM cells, cultured in the presence or absence of BMSCs. 8 In this study, patient MM cells were cultured for 2 days with perifosine (2.5, 5, 7.5 µM), in the presence (0.01, 0.1 µM) or absence of AZD6244, followed by MTT assay. Perifosine induced a dose-dependent increase in AZD6244-induced cytotoxicity (Fig. 5D , CI = 0.70). MM patient cells were similarly cultured with BMSCs for 3 days, in the presence or absence of AZD6244 (20 nM), perifosine (7.5 µM) or both, followed by MTT assay. AZD6244 and perifosine trigger synergistic cytotoxicity in adherent patient MM cells (Fig. 5E , CI = 0.70). These results indicate that AZD6244 enhances cytotoxicity induced by both conventional and novel agents.
Effect of AZD6244 on osteoclasts (OCs) in the BM
Since MM is associated with enhanced osteoclast (OC) activity, 33 and macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kappaB ligand (RANKL) induce differentiation and survival of OC precursor cells via ERK activation, 34 we next examined whether AZD6244 blocks ERK activation induced by only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From these cytokines in CD14+ OC precursor cells. Monocytic cells (CD14+) from MM patient PBMCs were incubated with M-CSF/RANKL-containing medium, in the presence or absence of AZD6244. Cell lysates were prepared and subjected to immunoblotting using anti-pERK1/2 and ERK1/2 Abs. Phosphorylation of ERK induced by these cytokines as early as 2h and sustained to 24h is completely blocked by AZD6244 (Fig. 6A) . We next assessed OC marker gene cathepsin K expression in CD14+ OC precursor cells after culture for 10 days with M-CSF/RANKL, in the presence or absence of AZD6244. AZD6244 decreased cathepsin K expression in a dose-dependent fashion (Fig. 6B) . Importantly, AZD6244 also inhibits integrinα v β 3 + OC formation in a dose-dependent manner: median % of mature OC is decreased from 81% (+ 4. 
AZD6244 inhibits human MM cell growth in vivo in a human plasmacytoma xenograft model
We next examined the in vivo efficacy of AZD6244 using our human plasmacytoma xenograft mouse model with OPM1 MM cells, which have an IC 50 of 5 µM AZD6244 in vitro (Fig. 1B) For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From
